Your browser doesn't support javascript.
loading
Prophylactic vaccination inducing anti-Env antibodies can result in protection against HTLV-1 challenge in macaques.
Nakamura-Hoshi, Midori; Ishii, Hiroshi; Nomura, Takushi; Nishizawa, Masako; Hau, Trang Thi Thu; Kuse, Nozomi; Okazaki, Midori; Ainai, Akira; Suzuki, Tadaki; Hasegawa, Hideki; Yoshida, Takeshi; Yonemitsu, Kenzo; Suzaki, Yuriko; Ami, Yasushi; Yamamoto, Hiroyuki; Matano, Tetsuro.
Afiliação
  • Nakamura-Hoshi M; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ishii H; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nomura T; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.
  • Nishizawa M; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Hau TTT; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kuse N; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Okazaki M; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ainai A; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Hasegawa H; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Yoshida T; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Yonemitsu K; Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Suzaki Y; Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Ami Y; Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Yamamoto H; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan; Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
  • Matano T; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan; Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. Electronic address: tmatano@niid.go.j
Mol Ther ; 32(7): 2328-2339, 2024 Jul 03.
Article em En | MEDLINE | ID: mdl-38734900
ABSTRACT
Humancell leukemia/T-lymphotropic virus type 1 (HTLV-1) infection occurs by cell-to-cell transmission and can induce fatal adultcell leukemia. Vaccine development is critical for the control of HTLV-1 transmission. However, determining whether vaccine-induced anti-Env antibodies can prevent cell-to-cell HTLV-1 transmission is challenging. Here, we examined the protective efficacy of a vaccine inducing anti-Env antibodies against HTLV-1 challenge in cynomolgus macaques. Eight of 10 vaccinated macaques produced anti-HTLV-1 neutralizing antibodies (NAbs) and were protected from an intravenous challenge with 108 HTLV-1-producing cells. In contrast, the 2 vaccinated macaques without NAb induction and 10 unvaccinated controls showed HTLV-1 infection with detectable proviral load after challenge. Five of the eight protected macaques were administered with an anti-CD8 monoclonal antibody, but proviruses remained undetectable and no increase in anti-HTLV-1 antibodies was observed even after CD8+ cell depletion in three of them. Analysis of Env-specific T cell responses did not suggest involvement of vaccine-induced Env-specific T cell responses in the protection. These results indicate that anti-Env antibody induction by vaccination can result in functionally sterile HTLV-1 protection, implying the rationale for strategies aimed at anti-Env antibody induction in prophylactic HTLV-1 vaccine development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus Linfotrópico T Tipo 1 Humano / Infecções por HTLV-I / Vacinação / Anticorpos Neutralizantes Limite: Animals / Humans Idioma: En Revista: Mol Ther Assunto da revista: BIOLOGIA MOLECULAR / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus Linfotrópico T Tipo 1 Humano / Infecções por HTLV-I / Vacinação / Anticorpos Neutralizantes Limite: Animals / Humans Idioma: En Revista: Mol Ther Assunto da revista: BIOLOGIA MOLECULAR / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão